Vestal Point Capital LP lifted its holdings in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 5.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,800,000 shares of the company's stock after buying an additional 135,000 shares during the quarter. Solid Biosciences makes up about 1.5% of Vestal Point Capital LP's holdings, making the stock its 22nd biggest holding. Vestal Point Capital LP owned 7.01% of Solid Biosciences worth $19,516,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of SLDB. Janus Henderson Group PLC bought a new position in shares of Solid Biosciences during the first quarter valued at approximately $23,935,000. Millennium Management LLC increased its position in Solid Biosciences by 135.7% during the 2nd quarter. Millennium Management LLC now owns 1,728,065 shares of the company's stock valued at $9,798,000 after buying an additional 994,984 shares in the last quarter. Vanguard Group Inc. raised its stake in Solid Biosciences by 283.9% during the first quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company's stock valued at $16,578,000 after buying an additional 920,404 shares during the last quarter. Marshall Wace LLP purchased a new position in Solid Biosciences during the second quarter valued at $1,554,000. Finally, Renaissance Technologies LLC boosted its holdings in Solid Biosciences by 303.6% in the second quarter. Renaissance Technologies LLC now owns 277,564 shares of the company's stock worth $1,574,000 after acquiring an additional 208,793 shares in the last quarter. 81.46% of the stock is owned by hedge funds and other institutional investors.
Solid Biosciences Stock Performance
Shares of SLDB stock traded up $0.01 on Friday, reaching $5.70. The stock had a trading volume of 62,337 shares, compared to its average volume of 343,940. The stock has a market cap of $227.77 million, a P/E ratio of -1.87 and a beta of 1.92. Solid Biosciences Inc. has a 1 year low of $2.70 and a 1 year high of $15.05. The company has a 50 day simple moving average of $6.13 and a 200 day simple moving average of $7.35.
Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.12). On average, equities research analysts anticipate that Solid Biosciences Inc. will post -2.85 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on SLDB shares. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Solid Biosciences in a research report on Thursday, November 7th. Barclays decreased their price objective on shares of Solid Biosciences from $18.00 to $15.00 and set an "overweight" rating for the company in a report on Wednesday, August 14th. William Blair upgraded Solid Biosciences to a "strong-buy" rating in a research note on Friday, August 30th. JPMorgan Chase & Co. decreased their price target on Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating for the company in a research note on Tuesday, November 12th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $15.14.
Check Out Our Latest Report on SLDB
About Solid Biosciences
(
Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Featured Articles
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
